Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma
•Maintenance chemotherapy improve the survival of stage N3 nasopharyngeal carcinoma.•Toxicity of maintenance chemotherapy was slightly and tolerable.•The optimal duration of Oral maintenance S1 is recommended for ≥12 cycles. This study aims to evaluate the effectiveness and the optimal maintenance p...
Gespeichert in:
| Veröffentlicht in: | Oral oncology 2021-07, Vol.118, p.105313-105313, Article 105313 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105313 |
|---|---|
| container_issue | |
| container_start_page | 105313 |
| container_title | Oral oncology |
| container_volume | 118 |
| creator | Zong, Jingfeng Liu, Yuhong Liang, Qiandong Xu, Hanchuan Chen, Bijuan Guo, Qiaojuan Xu, Yun Hu, Cairong Pan, Jianji Lin, Shaojun |
| description | •Maintenance chemotherapy improve the survival of stage N3 nasopharyngeal carcinoma.•Toxicity of maintenance chemotherapy was slightly and tolerable.•The optimal duration of Oral maintenance S1 is recommended for ≥12 cycles.
This study aims to evaluate the effectiveness and the optimal maintenance period of oral chemotherapy using S1 following definitive chemoradiotherapy in patients with stage N3 nasopharyngeal carcinoma (N3-NPC).
A retrospective review was performed for N3-NPC treatment with maintenance chemotherapy (MC) [chemoradiotherapy (CRT)-MC] or without MC (CRT-non-MC) following definitive CRT between May 2014 and December 2017. Toxicities during MC were recorded. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) were compared between CRT-MC and CRT-non-MC cohorts. The optimal duration of using maintenance S1 (MC-S1) was also analyzed.
A total of 304 patients with stage N3-NPC were identified, of whom 56 were treated with CRT-MC and 248 with CRT-non-MC. After a median follow-up of 48 months, significant differences in OS (74.9 vs. 91.7%; P = 0.003), PFS (60.7 vs. 83.7%; P = 0.001) and DMFS (68.8 vs. 85.5%; P = 0.015) were observed between the CRT-non-MC and CRT-MC groups. Skin hyperpigmentation, leukopenia and fatigue were common but not severe (grade 1–2) side effects of MC. The OS, DMFS and PFS were significantly higher for patients who received S1 administration over a period of ≥12 cycles compared with those who received |
| doi_str_mv | 10.1016/j.oraloncology.2021.105313 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2522186746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837521001366</els_id><sourcerecordid>2522186746</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-984c7afb5f212546643f9e9a8accc0fcc7ae1a16563d86224d0296718c8f0c473</originalsourceid><addsrcrecordid>eNqNUUuO1DAQjRCIGQaugCxWbNL4kzgJu9HwlUawgbVV45S73Ursxnb3KLfhBByCk1GtbkYsWbnk9yv7VdUrwVeCC_1mu4oJphhsnOJ6WUkuBQGtEupRdSn6bqh5O6jHNCvd173q2ovqWc5bznkrWv60ulBqaEigLqtf1-Psg88lQfExsOjY0ZzN4EPBAMEisxucY9lggt3CXExM_P65ICSapyne-7BmIzpyKf5wZicY_YNkhoX5eZcioXTH8j4d_IFCKGxHsRhKZve-bFgusEb2RbEAOe42kJawRiJaSNaHOMPz6omDKeOL83lVff_w_tvNp_r268fPN9e3tW2ULPXQN7YDd9c6KWTbaN0oN-AAPVhrubMEogChW63GXkvZjFwOuhO97R23TaeuqtcnX9r6xx5zMbPPFqcJAsZ9NrKVUvS6azRR356oNsWcEzqzS36m1Y3g5tiX2Zp_-zLHvsypLxK_POfs72YcH6R_CyLCuxMB6bUHj8lkSx9mcfQJbTFj9P-T8wewFLP_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2522186746</pqid></control><display><type>article</type><title>Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zong, Jingfeng ; Liu, Yuhong ; Liang, Qiandong ; Xu, Hanchuan ; Chen, Bijuan ; Guo, Qiaojuan ; Xu, Yun ; Hu, Cairong ; Pan, Jianji ; Lin, Shaojun</creator><creatorcontrib>Zong, Jingfeng ; Liu, Yuhong ; Liang, Qiandong ; Xu, Hanchuan ; Chen, Bijuan ; Guo, Qiaojuan ; Xu, Yun ; Hu, Cairong ; Pan, Jianji ; Lin, Shaojun</creatorcontrib><description>•Maintenance chemotherapy improve the survival of stage N3 nasopharyngeal carcinoma.•Toxicity of maintenance chemotherapy was slightly and tolerable.•The optimal duration of Oral maintenance S1 is recommended for ≥12 cycles.
This study aims to evaluate the effectiveness and the optimal maintenance period of oral chemotherapy using S1 following definitive chemoradiotherapy in patients with stage N3 nasopharyngeal carcinoma (N3-NPC).
A retrospective review was performed for N3-NPC treatment with maintenance chemotherapy (MC) [chemoradiotherapy (CRT)-MC] or without MC (CRT-non-MC) following definitive CRT between May 2014 and December 2017. Toxicities during MC were recorded. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) were compared between CRT-MC and CRT-non-MC cohorts. The optimal duration of using maintenance S1 (MC-S1) was also analyzed.
A total of 304 patients with stage N3-NPC were identified, of whom 56 were treated with CRT-MC and 248 with CRT-non-MC. After a median follow-up of 48 months, significant differences in OS (74.9 vs. 91.7%; P = 0.003), PFS (60.7 vs. 83.7%; P = 0.001) and DMFS (68.8 vs. 85.5%; P = 0.015) were observed between the CRT-non-MC and CRT-MC groups. Skin hyperpigmentation, leukopenia and fatigue were common but not severe (grade 1–2) side effects of MC. The OS, DMFS and PFS were significantly higher for patients who received S1 administration over a period of ≥12 cycles compared with those who received <12 cycles (3-year OS, 100 vs. 87.5%, P = 0.018; 3-year PFS, 93.9 vs. 67.9%, P = 0.006; 3-year DMFS, 97.1 vs. 67.9%, P = 0.002).
Using MC-S1 in patients with N3-NPC following definitive chemoradiotherapy achieved superior survival rate compared with the patients with non-MC. The side effects of MC-S1 were mild and tolerable. S1 should be maintained for ≥12 cycles.</description><identifier>ISSN: 1368-8375</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/j.oraloncology.2021.105313</identifier><identifier>PMID: 33940533</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols ; Chemoradiotherapy ; Disease-Free Survival ; Humans ; Maintenance Chemotherapy ; Nasopharyngeal carcinoma ; Nasopharyngeal Carcinoma - drug therapy ; Nasopharyngeal Carcinoma - radiotherapy ; Nasopharyngeal Neoplasms - drug therapy ; Nasopharyngeal Neoplasms - radiotherapy ; Neoplasm Recurrence, Local ; Optimal duration ; Retrospective Studies ; S-1</subject><ispartof>Oral oncology, 2021-07, Vol.118, p.105313-105313, Article 105313</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-984c7afb5f212546643f9e9a8accc0fcc7ae1a16563d86224d0296718c8f0c473</citedby><cites>FETCH-LOGICAL-c432t-984c7afb5f212546643f9e9a8accc0fcc7ae1a16563d86224d0296718c8f0c473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.oraloncology.2021.105313$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33940533$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zong, Jingfeng</creatorcontrib><creatorcontrib>Liu, Yuhong</creatorcontrib><creatorcontrib>Liang, Qiandong</creatorcontrib><creatorcontrib>Xu, Hanchuan</creatorcontrib><creatorcontrib>Chen, Bijuan</creatorcontrib><creatorcontrib>Guo, Qiaojuan</creatorcontrib><creatorcontrib>Xu, Yun</creatorcontrib><creatorcontrib>Hu, Cairong</creatorcontrib><creatorcontrib>Pan, Jianji</creatorcontrib><creatorcontrib>Lin, Shaojun</creatorcontrib><title>Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description>•Maintenance chemotherapy improve the survival of stage N3 nasopharyngeal carcinoma.•Toxicity of maintenance chemotherapy was slightly and tolerable.•The optimal duration of Oral maintenance S1 is recommended for ≥12 cycles.
This study aims to evaluate the effectiveness and the optimal maintenance period of oral chemotherapy using S1 following definitive chemoradiotherapy in patients with stage N3 nasopharyngeal carcinoma (N3-NPC).
A retrospective review was performed for N3-NPC treatment with maintenance chemotherapy (MC) [chemoradiotherapy (CRT)-MC] or without MC (CRT-non-MC) following definitive CRT between May 2014 and December 2017. Toxicities during MC were recorded. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) were compared between CRT-MC and CRT-non-MC cohorts. The optimal duration of using maintenance S1 (MC-S1) was also analyzed.
A total of 304 patients with stage N3-NPC were identified, of whom 56 were treated with CRT-MC and 248 with CRT-non-MC. After a median follow-up of 48 months, significant differences in OS (74.9 vs. 91.7%; P = 0.003), PFS (60.7 vs. 83.7%; P = 0.001) and DMFS (68.8 vs. 85.5%; P = 0.015) were observed between the CRT-non-MC and CRT-MC groups. Skin hyperpigmentation, leukopenia and fatigue were common but not severe (grade 1–2) side effects of MC. The OS, DMFS and PFS were significantly higher for patients who received S1 administration over a period of ≥12 cycles compared with those who received <12 cycles (3-year OS, 100 vs. 87.5%, P = 0.018; 3-year PFS, 93.9 vs. 67.9%, P = 0.006; 3-year DMFS, 97.1 vs. 67.9%, P = 0.002).
Using MC-S1 in patients with N3-NPC following definitive chemoradiotherapy achieved superior survival rate compared with the patients with non-MC. The side effects of MC-S1 were mild and tolerable. S1 should be maintained for ≥12 cycles.</description><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Chemoradiotherapy</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Maintenance Chemotherapy</subject><subject>Nasopharyngeal carcinoma</subject><subject>Nasopharyngeal Carcinoma - drug therapy</subject><subject>Nasopharyngeal Carcinoma - radiotherapy</subject><subject>Nasopharyngeal Neoplasms - drug therapy</subject><subject>Nasopharyngeal Neoplasms - radiotherapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Optimal duration</subject><subject>Retrospective Studies</subject><subject>S-1</subject><issn>1368-8375</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUUuO1DAQjRCIGQaugCxWbNL4kzgJu9HwlUawgbVV45S73Ursxnb3KLfhBByCk1GtbkYsWbnk9yv7VdUrwVeCC_1mu4oJphhsnOJ6WUkuBQGtEupRdSn6bqh5O6jHNCvd173q2ovqWc5bznkrWv60ulBqaEigLqtf1-Psg88lQfExsOjY0ZzN4EPBAMEisxucY9lggt3CXExM_P65ICSapyne-7BmIzpyKf5wZicY_YNkhoX5eZcioXTH8j4d_IFCKGxHsRhKZve-bFgusEb2RbEAOe42kJawRiJaSNaHOMPz6omDKeOL83lVff_w_tvNp_r268fPN9e3tW2ULPXQN7YDd9c6KWTbaN0oN-AAPVhrubMEogChW63GXkvZjFwOuhO97R23TaeuqtcnX9r6xx5zMbPPFqcJAsZ9NrKVUvS6azRR356oNsWcEzqzS36m1Y3g5tiX2Zp_-zLHvsypLxK_POfs72YcH6R_CyLCuxMB6bUHj8lkSx9mcfQJbTFj9P-T8wewFLP_</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Zong, Jingfeng</creator><creator>Liu, Yuhong</creator><creator>Liang, Qiandong</creator><creator>Xu, Hanchuan</creator><creator>Chen, Bijuan</creator><creator>Guo, Qiaojuan</creator><creator>Xu, Yun</creator><creator>Hu, Cairong</creator><creator>Pan, Jianji</creator><creator>Lin, Shaojun</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202107</creationdate><title>Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma</title><author>Zong, Jingfeng ; Liu, Yuhong ; Liang, Qiandong ; Xu, Hanchuan ; Chen, Bijuan ; Guo, Qiaojuan ; Xu, Yun ; Hu, Cairong ; Pan, Jianji ; Lin, Shaojun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-984c7afb5f212546643f9e9a8accc0fcc7ae1a16563d86224d0296718c8f0c473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Chemoradiotherapy</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Maintenance Chemotherapy</topic><topic>Nasopharyngeal carcinoma</topic><topic>Nasopharyngeal Carcinoma - drug therapy</topic><topic>Nasopharyngeal Carcinoma - radiotherapy</topic><topic>Nasopharyngeal Neoplasms - drug therapy</topic><topic>Nasopharyngeal Neoplasms - radiotherapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Optimal duration</topic><topic>Retrospective Studies</topic><topic>S-1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zong, Jingfeng</creatorcontrib><creatorcontrib>Liu, Yuhong</creatorcontrib><creatorcontrib>Liang, Qiandong</creatorcontrib><creatorcontrib>Xu, Hanchuan</creatorcontrib><creatorcontrib>Chen, Bijuan</creatorcontrib><creatorcontrib>Guo, Qiaojuan</creatorcontrib><creatorcontrib>Xu, Yun</creatorcontrib><creatorcontrib>Hu, Cairong</creatorcontrib><creatorcontrib>Pan, Jianji</creatorcontrib><creatorcontrib>Lin, Shaojun</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zong, Jingfeng</au><au>Liu, Yuhong</au><au>Liang, Qiandong</au><au>Xu, Hanchuan</au><au>Chen, Bijuan</au><au>Guo, Qiaojuan</au><au>Xu, Yun</au><au>Hu, Cairong</au><au>Pan, Jianji</au><au>Lin, Shaojun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2021-07</date><risdate>2021</risdate><volume>118</volume><spage>105313</spage><epage>105313</epage><pages>105313-105313</pages><artnum>105313</artnum><issn>1368-8375</issn><eissn>1879-0593</eissn><abstract>•Maintenance chemotherapy improve the survival of stage N3 nasopharyngeal carcinoma.•Toxicity of maintenance chemotherapy was slightly and tolerable.•The optimal duration of Oral maintenance S1 is recommended for ≥12 cycles.
This study aims to evaluate the effectiveness and the optimal maintenance period of oral chemotherapy using S1 following definitive chemoradiotherapy in patients with stage N3 nasopharyngeal carcinoma (N3-NPC).
A retrospective review was performed for N3-NPC treatment with maintenance chemotherapy (MC) [chemoradiotherapy (CRT)-MC] or without MC (CRT-non-MC) following definitive CRT between May 2014 and December 2017. Toxicities during MC were recorded. Overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional relapse-free survival (LRRFS) were compared between CRT-MC and CRT-non-MC cohorts. The optimal duration of using maintenance S1 (MC-S1) was also analyzed.
A total of 304 patients with stage N3-NPC were identified, of whom 56 were treated with CRT-MC and 248 with CRT-non-MC. After a median follow-up of 48 months, significant differences in OS (74.9 vs. 91.7%; P = 0.003), PFS (60.7 vs. 83.7%; P = 0.001) and DMFS (68.8 vs. 85.5%; P = 0.015) were observed between the CRT-non-MC and CRT-MC groups. Skin hyperpigmentation, leukopenia and fatigue were common but not severe (grade 1–2) side effects of MC. The OS, DMFS and PFS were significantly higher for patients who received S1 administration over a period of ≥12 cycles compared with those who received <12 cycles (3-year OS, 100 vs. 87.5%, P = 0.018; 3-year PFS, 93.9 vs. 67.9%, P = 0.006; 3-year DMFS, 97.1 vs. 67.9%, P = 0.002).
Using MC-S1 in patients with N3-NPC following definitive chemoradiotherapy achieved superior survival rate compared with the patients with non-MC. The side effects of MC-S1 were mild and tolerable. S1 should be maintained for ≥12 cycles.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33940533</pmid><doi>10.1016/j.oraloncology.2021.105313</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-8375 |
| ispartof | Oral oncology, 2021-07, Vol.118, p.105313-105313, Article 105313 |
| issn | 1368-8375 1879-0593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2522186746 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols Chemoradiotherapy Disease-Free Survival Humans Maintenance Chemotherapy Nasopharyngeal carcinoma Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Carcinoma - radiotherapy Nasopharyngeal Neoplasms - drug therapy Nasopharyngeal Neoplasms - radiotherapy Neoplasm Recurrence, Local Optimal duration Retrospective Studies S-1 |
| title | Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T18%3A11%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Administration%20of%20oral%20maintenance%20chemotherapy%20for%201%C2%A0year%20following%20definitive%20chemoradiotherapy%20may%20improve%20the%20survival%20of%20patients%20with%20stage%20N3%20nasopharyngeal%20carcinoma&rft.jtitle=Oral%20oncology&rft.au=Zong,%20Jingfeng&rft.date=2021-07&rft.volume=118&rft.spage=105313&rft.epage=105313&rft.pages=105313-105313&rft.artnum=105313&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/j.oraloncology.2021.105313&rft_dat=%3Cproquest_cross%3E2522186746%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2522186746&rft_id=info:pmid/33940533&rft_els_id=S1368837521001366&rfr_iscdi=true |